Literature DB >> 9849614

Hammerhead ribozyme design and application.

M Amarzguioui1, H Prydz.   

Abstract

The emerging knowledge about RNA-based enzymes has already had great impact on our concept of evolutionary history, making the 'RNA world' more likely. It may well have an equally important impact on the diagnostic and therapeutic practices of human and veterinary medicine in the next decade. We are not quite there yet. This review addresses the design and application of hammerhead ribozymes, two aspects of a conserved and most commonly studied and used enzymatically active entity among the RNA enzymes. The emerging picture is one of great diversity. There is at this stage no general cell model nor a clearly preferable ribozyme structure. Each and every cell line (and tissue) may be unique in that they vary with respect to structural requirements for optimal uptake, activity and stability of ribozymes. We may have seen only the tip of the iceberg when it comes to RNA-based enzymes and their roles in biology and medicine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849614     DOI: 10.1007/s000180050247

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  14 in total

1.  Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.

Authors:  M Amarzguioui; G Brede; E Babaie; M Grotli; B Sproat; H Prydz
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  A selection system for identifying accessible sites in target RNAs.

Authors:  W H Pan; H F Devlin; C Kelley; H C Isom; G A Clawson
Journal:  RNA       Date:  2001-04       Impact factor: 4.942

3.  Tolerance for mutations and chemical modifications in a siRNA.

Authors:  Mohammed Amarzguioui; Torgeir Holen; Eshrat Babaie; Hans Prydz
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

4.  Synthesis of ribozyme against vascular endothelial growth factor165 and its biological activity in vitro.

Authors:  Zhong-Ping Gu; Yun-Jie Wang; Yu Wu; Jin-Ge Li; Nong-An Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

5.  A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.

Authors:  Edwin H Yau; Mark C Butler; Jack M Sullivan
Journal:  Exp Eye Res       Date:  2016-05-25       Impact factor: 3.467

6.  Selection, design, and characterization of a new potentially therapeutic ribozyme.

Authors:  Shawn P Zinnen; Kristal Domenico; Mike Wilson; Brent A Dickinson; Amber Beaudry; Victor Mokler; Andrew T Daniher; Alex Burgin; Leonid Beigelman
Journal:  RNA       Date:  2002-02       Impact factor: 4.942

7.  RNA-Redesign: a web server for fixed-backbone 3D design of RNA.

Authors:  Joseph D Yesselman; Rhiju Das
Journal:  Nucleic Acids Res       Date:  2015-05-11       Impact factor: 16.971

8.  Automated design of hammerhead ribozymes and validation by targeting the PABPN1 gene transcript.

Authors:  Nawwaf Kharma; Luc Varin; Aida Abu-Baker; Jonathan Ouellet; Sabrine Najeh; Mohammad-Reza Ehdaeivand; Gabriel Belmonte; Anas Ambri; Guy Rouleau; Jonathan Perreault
Journal:  Nucleic Acids Res       Date:  2015-11-02       Impact factor: 16.971

Review 9.  Modulating RNA structure and catalysis: lessons from small cleaving ribozymes.

Authors:  Cedric Reymond; Jean-Denis Beaudoin; Jean-Pierre Perreault
Journal:  Cell Mol Life Sci       Date:  2009-08-30       Impact factor: 9.261

Review 10.  Gene therapy in animal models of autosomal dominant retinitis pigmentosa.

Authors:  Brian Rossmiller; Haoyu Mao; Alfred S Lewin
Journal:  Mol Vis       Date:  2012-10-06       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.